OTC Markets OTCQB - Delayed Quote USD

Marizyme, Inc. (MRZM)

0.0041

-0.0007

(-14.58%)

At close: January 10 at 10:51:48 AM EST

Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft

JUPITER, FL - (NewMediaWire) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft(R) will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20oC...

NewMediaWire 8 months ago

MRZM
-14.58%
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

JUPITER, FL - (NewMediaWire) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the "Agreement") with Qualigen Therapeutics, Inc. ("Qualigen") (NASDAQ: QLGN) to advance the commercialization of Mar...

NewMediaWire 8 months ago

MRZM
-14.58%
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit sol

GlobeNewswire 8 months ago

QLGN

MRZM
-14.58%

Performance Overview

Return	MRZM	S&P 500
YTD	-50.00%	-1.35%
1-Year	-96.27%	+22.51%
3-Year	-99.76%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Marizyme, Inc. (MRZM)

Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

Performance Overview